Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909597 · ClinicalTrials.gov registry record · Phase 3
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
NCT00909597 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 756 participants.
The verdict
NCT00909597, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
Study Summary
This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.
Interventions
- DRUG pioglitazone
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909597
The ClinicalTrials.gov registry entry for NCT00909597 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT00909597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909597 about?
NCT00909597 is a clinical study titled "A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes". This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial scr...
What is the current status of trial NCT00909597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2009-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00909597?
The interventions under investigation include: pioglitazone (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT00909597?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.